Viatris

VTRS

시가총액 US$214억

PITTSBURGH, Oct. 16, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved RYZUMVI® (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in adults. RYZUMVI is currently approved in the United States for the treatment of pharmacologically-induced mydriasis and is the only commercially available FDA-approved product for that use.

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Pacira BioSciences, Inc. (NasdaqGS: PCRX) to Viatris Inc. (NasdaqGS: VTRS). Under the terms of the proposed transaction, shareholders of Pacira will receive $36.50 in cash for each share of Pacira that they own. KSF is seeking to determine whether this consideration and the process that led to it ar.

VTRS is set to acquire PCRX for $1.65 billion in cash, adding two marketed pain therapies and a clinical-stage gene therapy candidate to expand its non-opioid pain portfolio.

I analyze 84 top Ten-Year tenured dividend dogs, focusing on yield-based selection and free cash flow safety for October 2026. Chimera Investment, Mach Natural Resources, and Matthews International lead projected net gains, with average estimated returns of 48.6% on $10k invested. Fifteen of thirty-six 'safer' dividend dogs meet the IDEAL standard, with annual dividends from $1k invested exceeding their share price.

Bala Cynwyd, Pennsylvania--(Newsfile Corp. - October 8, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Pacira BioSciences, Inc. ("Pacira BioSciences" or the "Company") (NASDAQ: PCRX) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Viatris Inc. (NASDAQ: VTRS) for $36.50 per share in cash, representing an aggregate equity value of $1.65 billion. The investigation concerns whether the Pacira BioSciences Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the proposed transaction is paying fair value to shareholders of the Company.

Viatris pledged Thursday to buy small biotech company Pacira Biosciences for $1.65 billion, sending Pacira stock skyrocketing.

Viatris has agreed to buy pain-drug maker Pacira BioSciences for $1.65 billion in a deal that expands the healthcare company's medicines portfolio.

Viatris said on Thursday ‌it will buy Pacira Biosciences for $1.65 billion, adding the ​pain therapy maker's ​products to its portfolio.

Adds Two Marketed, Patent-Protected, High-Margin Medicines in the U.S., EXPAREL® and ZILRETTA®, and Expects to Expand the Products' Reach Across Selected Markets Within Its International Infrastructure Expands U.S. Innovative Medicines Commercial, Market Access, Medical Affairs and Global R&D Capabilities Expected to Be Synergistic With Viatris' Fast-Acting Meloxicam Opportunity Deal Anticipated to Close By the End of 2026 and to Be Immediately Accretive to Viatris' Financial Guidance Metrics Transaction Consistent With Viatris' Disciplined and Balanced Capital Allocation Strategy and Preserves Financial Flexibility PITTSBURGH and BRISBANE, Calif. , Oct. 8, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, and Pacira BioSciences, Inc. (Nasdaq: PCRX), a leader in innovative non-opioid pain therapies, today announced that they have entered into a definitive agreement under which Viatris has agreed to acquire all of the outstanding shares of common stock of Pacira for $36.50 per share in cash, representing an aggregate equity value of $1.65 billion.

Investors looking for stocks in the Medical Services sector might want to consider either Viatris (VTRS) or Avantor, Inc. (AVTR). But which of these two stocks is more attractive to value investors?